KALA · XBRL financial data

KALA BIO financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KALA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Research and development	5,554	—	6,351	5,317	5,168	—	6,055	6,232	6,127	—	61	59
Selling, general and administrative	4,952	4,623*	—	—	—	—	—	—	—	—	—	—
General and administrative	4,952	4,623*	5,422	4,317	4,400	4,201*	4,593	4,643	4,534	9,859*	1,741	1,662
Total operating expenses	8,762	9,619*	11,931	9,605	9,988	9,459*	10,669	11,028	7,239	10,225*	1,802	1,721
Operating income (loss)	(8,762)	(9,619)*	(11,931)	(9,605)	(9,988)	(9,459)*	(10,669)	(11,028)	(7,239)	(10,225)*	(1,802)	(1,721)
Interest income	708	610*	504	504	570	478*	463	407	270	0*	74	140
Interest expense	1,459	1,468*	1,455	1,458	1,478	1,392*	1,091	1,081	963	141*	—	—
Other income (expense)	(2,161)	(5)*	—	—	—	—	—	—	(112)	5,259*	107	0*
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(8,704)	(8,627)*	(11,807)	(9,579)	(8,950)	(8,175)*	(8,947)	(11,155)	(7,564)	686*	(1,621)	(1,581)
Earnings per share, basic‡ USD per share	(170.50)	(159.00)*	(210.00)	(158.00)	(96.50)	—	(70.50)	(85.50)	(53.50)	—	(7.00)	(21.32)
Earnings per share, diluted‡ USD per share	(170.50)	(159.00)*	(210.00)	(158.00)	(96.50)	—	(70.50)	(85.50)	(53.50)	—	(7.00)	(21.32)
Weighted average shares, basic‡ thousands of shares	51	54*	56	61	93	94*	127	130	141	—	237	74
Weighted average shares, diluted‡ thousands of shares	51	54*	56	61	93	94*	127	130	141	—	237	74

‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (May 2026); filings made before it reported them unadjusted.
† Share count changed about 113x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/50 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 52x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (KALA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	56,063	50,895	48,478	54,197	49,202	51,181	42,222	31,942	21,096	7,557	1,764	229
Short-term investments	—	—	—	—	—	—	—	—	—	—	7,000	7,000
Prepaid and other current assets	1,839	1,975	1,609	4,656	2,077	1,616	3,495	1,721	3,178	1,933	3,554	3,353
Total current assets	57,902	52,870	50,087	58,853	51,279	52,797	45,717	33,663	24,274	9,490	12,318	10,582
Property and equipment, net	802	753	714	617	762	749	695	657	603	—	—	—
Right-of-use asset	2,102	2,025	1,945	1,863	1,778	1,691	1,601	1,507	—	—	—	—
Total assets	61,120	55,949	53,033	61,606	54,079	55,483	48,252	36,053	25,021	9,490	12,318	10,582
Accounts payable	787	919	732	665	711	628	931	658	917	986	1,044	1,142
Accrued liabilities	6,260	6,018	4,810	3,924	4,497	—	—	—	—	—	—	—
Current portion of long-term debt	—	—	5,992	11,985	17,977	10,336	15,503	9,511	28,411	—	—	—
Total current liabilities	10,301	8,346	11,879	19,190	23,867	16,956	22,975	16,016	32,574	2,494	1,557	1,538
Long-term debt	33,878	34,190	28,510	22,832	17,162	20,102	15,121	18,786	—	—	—	—
Lease liability, non-current	1,880	1,799	1,715	1,628	1,532	1,434	1,332	1,227	1,112	—	—	—
Total liabilities	49,897	48,445	46,372	47,889	47,220	43,151	42,544	39,259	33,686	2,494	1,557	1,538
Accumulated deficit	(620,782)	(629,409)	(641,216)	(650,795)	(659,745)	(667,920)	(676,867)	(688,022)	(695,586)	(694,900)	(696,521)	(698,102)
Total stockholders' equity	11,223	7,504	6,661	13,717	6,859	12,332	5,708	(3,206)	(8,665)	6,996	10,761	9,044
Total liabilities and equity	61,120	55,949	53,033	61,606	54,079	55,483	48,252	36,053	25,021	9,490	12,318	10,582
Common shares outstanding (cover page)‡ thousands of shares	54	56	56	92	92	129	129	140	164	18,590	372	19,340

‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (May 2026); filings made before it reported them unadjusted.
† Share count changed about 113x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/50 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 52x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (KALA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(8,704)	(8,627)*	(11,807)	(9,579)	(8,950)	(8,175)*	(8,947)	(11,155)	(7,564)	686*	(1,621)	(1,581)
Stock-based compensation	2,403*	2,374*	2,376	1,883*	2,036*	2,094*	2,310	2,240*	2,044*	401*	(471)	(136)*
Depreciation and amortization	79*	70*	66	61*	63*	69*	68	67*	128*	54*	—	—
Net cash from operating activities	(2,952)*	(7,696)*	(10,844)	(9,215)*	(4,725)*	(4,598)*	(8,824)	(16,558)	(10,877)*	(4,556)*	(2,895)	(1,535)*
Net cash from investing activities	9,719*	(7)*	(13)	(36)*	(90)*	(69)*	—	—	1*	0*	(7,000)	0*
Proceeds from issuing common stock	0*	570*	—	—	0*	923*	—	—	—	year only	—	—
Net cash from financing activities	40*	2,535*	8,440	14,970*	(180)*	6,646*	(135)	(2,530)*	30*	(8,983)*	4,102	0*
Net change in cash	6,807*	(5,168)*	(2,417)	5,719*	(4,995)*	1,979*	(8,959)	(10,280)*	(10,846)*	(13,539)*	(5,793)	(1,535)*

† Share count changed about 113x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/50 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 52x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.